Four paraoxonase gene polymorphisms in 11 212 cases of coronary heart disease and 12 786 controls: Meta-analysis of 43 studies

Lancet

Volumn 363, Issue 9410, 2004, Pages 689-695

  Wheeler, Jeremy G ^a   Keavney, Bernard D ^b   Watkins, Hugh ^c   Collins, Rory ^d   Danesh, John ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE;

ALLELE; ARTICLE; CARDIOVASCULAR RISK; DNA POLYMORPHISM; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC VARIABILITY; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL;

EID: 1542331537     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)15642-0     Document Type: Article

References (58)

1. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A. Paraoxonase: biochemistry, genetics and relationships to plasma lipoproteins. Curr Opin Lipidol. 7:1996;69-76.
2. Mackness M.I., Mackness B., Durrington P., et al. Paraoxonase and coronary heart disease. Curr Opin Lipidol. 9:1998;319-324.
3. James R., Leviev I., Ruiz J., Passa P., Froguel P., Blatter-Garin M. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes. 40:2000;1390-1393.
4. Leviev I., James R. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol. 20:2000;516-521.
5. Adkins S., Gan K.N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 52:1993;598-608.
6. Lohmueller K.E., Pearce C.L., Pike P., Lander E.S., Hirschhorn J.N. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 33:2003;177-182.
7. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 21:2001;473-480.
8. Mackness B., Davies G., Turkie W., et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol. 21:2001;1451-1457.
9. Cascorbi I., Laule M., Mrozikiewicz P., et al. Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease. Pharmacogenetics. 9:1999;755-761.
10. Imai Y., Morita H., Kurihara H., et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis. 149:2000;435-442.
11. Wang X., Fan Z., Huang J., et al. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol. 23:2003;328-334.
12. Leus F.R., Zwart M., Kastelein J.J.P., Voorbij HAM. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis. 154:2001;641-649.
13. Cherry N., Mackness M., Durrington P., et al. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet. 359:2002;763-764.
14. Leviev I., Righetti A JR. Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med. 79:2001;457-463.
15. Arca A., Ombres D., Montali A., et al. PONI L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest. 32:2002;9-15.
16. Chen Q., Reis S.E., Kammerer C.M., et al. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet. 72:2003;13-22.
17. Watzinger N., Schmidt H., Schumacher M., et al. Human paraoxonase 1 gene polymorphisms and the risk of coronary heart disease:a community-based study. Cardiology. 98:2002;116-122.
18. Pan J.P., Lai S.T., Chiang S.C., Chou S.C., Chiang A.N. The risk of coronary artery disease in population of Taiwan is associated with Cys-Ser 311 polymorphism of human paraoxonase (PON)-2 gene. Zhonghua Yi Xue Za Zhi. 65:2002;411-412.
19. Hong S.H., Song J., Min W.K., Kim J.Q. Genetic variations of the paraoxonase gene in patients with coronary artery disease. Clin Biochem. 34:2001;475-481.
20. Osei-Hyiaman D., Hou L., Mengbai F., Zhiyin R., Zhiming Z., Kano K. Coronary artery disease risk in Chinese type 2 diabetics: is there a role for paraoxonase 1 gene (Q192R) polymorphism? Eur J Endocrinol. 144:2001;639-644.
21. Pfohl M., Koch M., Enderle M., et al. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes. 48:1999;623-627.
22. Aynacioglu A.S., Kepekci Y. The human paraoxonase Gln-Arg 192 (Q/R) polymorphism in Turkish patients with coronary artery disease. Int J Cardiol. 74:2002;33-37.
23. Gardemann A., Philipp M., Hess K., Katz N., Tillmans H., Haberbosch W. The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis. 152:2000;421-431.
24. Ko Y-L, Ko Y-S, Wang S-M, et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis. 141:1998;259-264.
25. Ombres D., Pannitteri G., Montali A., et al. The Gln-Arg 192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol. 18:1998;1611-1616.
26. Rice G.I., Ossei-Gerning N., Stickland M., Grant P.J. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease. Coron Artery Dis. 8:1997;677-682.
27. Sanghera D.K., Saha N., Kamboh M.I. The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis. 136:1998;217-223.
28. Sanghera D.K., Saha N., Aston C.E., Kamboh M.I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol. 17:1997;1067-1073.
29. Zama T., Murata M., Matsubara Y., et al. A 192 Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol. 17:1997;3565-3569.
30. Sanghera D.K., Aston C.E., Saha N., Kamboh I. DNA polymorphisms in two paraoxonase genes (PON1 and PON 2) are associated with the risk of coronary heart disease. Am J Hum Genet. 62:1998;36-44.
31. Pati N., Pati U. Paraoxonase gene polymorphism and coronary artery disease in Indian subjects. Int J Cardiol. 66:1998;165-168.
32. Blatter-Garin M.C., James R.W., Dussoix P., et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. J Clin Invest. 99:1997;62-66.
33. Ruiz J., Blanché H., James R., et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346:1995;869-872.
34. Serrato M., Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 96:1995;3005-3008.
35. Suehiro T., Nakauchi Y., Yamamoto M., et al. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol. 57:1996;69-73.
36. Jarvik G., Rozek L., Brophy V., et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1 192 or PON1 55 genotype. Arterioscler Thromb Vasc Biol. 20:2000;2441-2447.
37. Letellier C., Durou M.R., Jouanolle A.M., Le-Gall J.Y., Poirier J.Y., Ruelland A. Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications. Diabetes Metab. 28:2002;297-304.
38. Hasselwander O., Savage D.A., McMaster D., et al. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int. 56:1999;289-298.
39. Yamada Y., Izawa H., Ichihara S., et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 347:2002;1916-1923.
40. Ayub A., Mackness M.I., Arrol S., Mackness B., Patel J., Durrington P.N. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. 19:1997;330-335.
41. Heijmans B., Westendorp G., Lagaay A., Knook D., Kluft C., Slagboom P. Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis. 149:2000;91-97.
42. Salonen J.T., Malin R., Tuomainen T-P, Nyyssönen K., Lakka T.A., Lehtimäki T. Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men:prospective nested case-control study. BMJ. 319:1999;487-489.
43. Sen-Banerjee S., Siles X., Campos H. Tobacco smoking modifies association between Gln-Arg192 polymorphism of human paraoxonase gene and risk of myocardial infarction. Arterioscler Thromb Vasc Biol. 20:2000;2120-2126.
44. Ferre N., Tous M., Paul A., et al. Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin Biochem. 35:2003;197-203.
45. Odawara M., Tachi Y., Yamashita K. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin dependant diabetes mellitus. J Clin Endocrinol Metab. 82:1997;2257-2260.
46. Antikainen M., Murtomaki S., Syvanne M., et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest. 98:1996;883-885.
47. Aubo C., Senti M., Marrugat J., et al. Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus. Eur Heart J. 21:2000;33-38.
48. Herrmann S-M, Blanc H., Poirer O., et al. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis. 126:1996;299-303.
49. Sentí M., Tomás M., Marrugat J., Elosua R. Paraoxonase 1-192 polymorphism modulates the nonfatal myocardial infarction risk associated with decreased HDLs. Arterioscler Thromb Vasc Biol. 21:2001;415-420.
50. Turban S., Fuentes F., Ferlic L., et al. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis. 154:2001;633-640.
51. Humbert R., Adler D.A., Disteche C.M., Omiecinski C., Furlong C. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 3:1993;73-76.
52. Clayton D., McKeigue P.M. Epidemiological methods for studying genes and environmental factors in complex disease. Lancet. 358:2001;1356-1360.
53. Youngman LD, Keavney BD, Palmer A. Plasma fibrinogen and fibrinogen genotypes in 4685 cases of myocardial infarction and in 6002 controls: test of causality by "Mendelian randomisation". Circulation 2000; 102 [suppl II]: 31-32.
54. Mackness B., Durrington P., McElduff P., et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 107:2003;2775.
55. Keavney B., McKenzie C., Parish S., et al. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. Lancet. 355:2000;434-442.
56. Colhoun H.M., McKeigue P.M., Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet. 361:2003;865-872.
57. Hirschhorn J.N., Lohmueller K.E., Byrne E., Hirschhorn K. A comprehensive review of genetic association studies. Genet Med. 4:2002;45-61.
58. Ionnidis J.P.A., Trikalinos T.A., Ntzani E.E., Contopoulos-Ioannidis D.G. Genetic associations in large versus small studies: an empirical assessment. Lancet. 361:2003;567-571.